Biotech China 2014
3rd WIN Symposium
Palais des Congrès de Paris
Le Palais des Congrès de Paris 2 Place de la Porte Maillot, 75017 Paris, France 01 53 81 78 09
Paris, France
http://www.winconsortium.org/symposium.html
The Worldwide Innovative Networking (WIN) Consortium invites you to attend the third WIN
Annual Symposium, dedicated this year to a very challenging topic: Gateways to increasing
the efficacy of cancer diagnostics and therapeutics.
The WIN Consortium, initiated by Institut Gustave Roussy (France) and The University of Texas
MD Anderson Cancer Center (USA), is a non-profit organization bringing together cancer
centers from five continents to address the challenge of increasing the efficacy of global cancer
healthcare through personalized therapy. The WIN Consortium aims to foster and facilitate
cooperation between cancer centers, pharmaceutical and technology companies, patient
advocacy groups, governmental institutions and other stakeholders in the field of early diagnosis
and personalized, biomarker-driven treatment of cancer. The goal is to accelerate integration
of groundbreaking discoveries into clinical practice in diverse populations, in order to significantly
improve clinical outcomes and the quality of life of cancer patients, worldwide.
Examples of questions for discussion and debate during WIN3 include:
• Determining the efficacy of targeted cancer therapies
• Determining the efficacy of genetic and molecular biomarkers for selecting
patients likely to respond to targeted therapeutics
• Improved design of clinical trials with targeted therapies. Efficient
comparisons. Appropriate endpoints. Combinations of therapies.
Is randomization necessary?
• Building more effective collaborations between academia, industry
and patients.
• Innovation in technologies that identify genetic and molecular
abnormalities in cancers.
• Improvements in bioinformatics and applications of systems biology.
We aim to create a forum for open discussion, in which your expertise and input from all stakeholders
in cancer drug development are crucial. The WIN Consortium was created to accelerate
the pace and reduce the cost of translating effective cancer treatments to the bedside. We
need every member and thought leader in the field to be committed and engaged to succeed
in our mission.
The 22 founding member institutions of the WIN Consortium invite you to join in this forum,
and we invite you and your institution to join the Consortium

Schedule of Presentations:

Wednesday, July 6, 2011
07:30:00 REGISTRATION
08:15:00 WELCOME AND OPENING OF THE SYMPOSIUM Alexander Eggermont
08:30:00 KEYNOTE LECTURE | Challenges and opportunities in personalized cancer therapy and cooperation between the Pharmaceutical Industry and Academia. The WIN Consortium model and operational goals JOHN MENDELSOHN
08:50:00 SESSION 1 | THE ERA OF PERSONALIZED MEDICINE AND OF SIGNIFICANT PROGRESS FOR PATIENT CARE Stephen Friend
08:55:00 Dawn of the personalized healthcare era | a significant step forward in patient care
09:20:00 Genomic Cancer Care Alliance TACT Trial: multi-center feasibility study for whole genome sequencing in therapy selection | Challenges for academics and industry Paul R. Billings
09:45:00 Predict efficacy of therapeutics in day to day clinics: experimental models versus directly exploring tumor molecular portraits David Sidransky
10:10:00 Predicting efficacy of therapeutics in clinical trials | filling the gap between pre-clinical models and phase I clinical trials D. Gary Gilliland
10:45:00 Early diagnostics | a clue for enhanced global efficacy in oncology: Joining WIN Consortium for a global effort to detect lung cancers in earlier stage Samir Hanash
11:10:00 Coffee Break, network discussions and poster review
11:25:00 SESSION 2 | CHALLENGES OF COMBINING TARGETED THERAPIES Richard L Schilsky
11:30:00 Vemurafinib (a BRAF inhibitor) - The thrill of efficacy and the challenge of emerging tumor resistance Robert Wasserman
12:10:00 Academic and Pharmaceutical Industry perspective: Increasing the predictive value of early phase clinical trials to screen new agents or combinations likely to be efficacious in a defined patient population
12:30:00 ROUND TABLE - PANEL OF EXPERTS - FORUM OF OPEN DISCUSSION WITH ATTENDEES | Monotherapies or combined therapeutics? Clinically addressing the complexity of molecular pathways in cancer: How can we develop the most relevant combination beyond individual Pharma/Biotech pipelines: a risk sharing approach for the benefit of the patient RICHARD SCHILSKY, JOHN MENDELSOHN, D. Gary Gilliland
13:15:00 Lunch, network discussions and poster review
13:20:00 CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Committee on standardization of biobanking and molecular analyses of biopsies in clinical trials (open to the public) Ignacio I. Wistuba, DINGWEY YE, RITA MULHERKAR, Gerald Batist, VLADIMIR LAZAR, STANLEY HAMILTON
14:10:00 CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Committee on audit and compliance in clinical trials (open to the public) GILLES VASSAL, SOO KHEE CHEE, RICHARD SCHILSKY
14:35:00 SESSION 3 | NEW BIOMARKER STRATEGIES IN CLINICAL TRIALS D. Gary Gilliland, Samir Hanash
14:40:00 Molecular Diagnostics and Functional imaging Ian A. Wilson
15:05:00 Pharmacogenomic testing - matching patients with targeted drugs Lillian L. Siu
15:30:00 Genetic background, susceptibility to cancer, and impact on personalized medicine
15:55:00 Using biomarkers prospectively in adaptive trials Donald Berry
16:20:00 A comprehensive and adaptive model of biomarker strategies in clinical trials. Highlights of the WIN Consortium workshop on standardization and use of biopsies Vladimir Lazar
16:55:00 Personalised Healthcare | the Diagnostic considerations
17:20:00 Coffee Break, network discussions and poster review
17:35:00 SESSION 4 | STRATEGIC ALLIANCES TO FIGHT CANCER Alexander Eggermont, JOHN MENDELSOHN
17:40:00 US Academic/Industry collaborations for predictive biomarkers in early clinical development: perspectives of joining WIN Consortium efforts Gail Gail Eckhardt
18:00:00 Molecular driven clinical trials: the EORTC Network of Core Institutions (NOCI) and perspectives of interactions with WIN Consortium D. Lacombe
18:20:00 Efforts by the European cancer community to reinforce cooperation and increase global efficacy in therapeutics. Achievements and perspectives: a specific role for WIN Consortium JU CE
18:40:00 Innovation in Cancer healthcare, a 21st century project for states and society | French initiatives
19:00:00 Beyond the shock of cancer disease | Education worldwide, prevention and their impact on improving quality of life of cancer patients
19:30:00 WELCOME COCKTAIL
Thursday, July 7, 2011
07:30:00 REGISTRATION
08:25:00 SESSION 5 | DISCOVERY AND VALIDATION OF NEW TARGETS AND BIOMARKERS SOO KHEE CHEE, Daniel Louvard
08:30:00 Integrating pre-clinical models with clinical data - drivers and passengers Leroy E Hood
08:55:00 Improving the prospects of preclinical models to predict investigational drug efficacy in the clinic and clinical trials Robert S Kerbel
09:20:00 How do we study network perturbations in clinical specimens? How do we select “drivers” of malignancies? Stephen Friend
09:45:00 New targets and innovative therapeutics Kenneth C Anderson
10:10:00 An example | Targeting the PI3K pathway - focused development for the treatment of cancer Samit Hirawat
10:35:00 PANEL OF EXPERTS - FORUM OF OPEN DISCUSSION WITH ATTENDEES | Innovative and informative pre-clinical models and translation to clinic
11:00:00 Coffee Break, network discussions and poster review
11:25:00 SESSION 6 | WIN-WIN MODELS | CONCEPTS FOR SUCCESS DINGWEY YE
11:30:00 Academic perspective | how to share ideas, resources and intellectual property? What are the Win-Win models? MARCO PIEROTTI
11:50:00 A successful interaction between Academia and Pharma – The NERVIANO Medical Sciences – and Oncology Network of Lombardy
12:10:00 JAK 2 – from basic concepts to clinical diagnostics and therapeutics applications
12:30:00 Lunch, network discussions and poster review
12:35:00 CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Scientific Committee on the design of clinical trials, data processing and access (open to the public) J. Tabernero, SOO KHEE CHEE, Donald Berry, Jean- -Charles Soria, Razelle Kurzrock
13:00:00 CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Publicity and Fundraising Task Force (open to the public) Vladimir Lazar, Alexander Eggermont
13:30:00 CONCURRENT WORKSHOPS | Workshop of the WIN Consortium Committee on membership (not open to the public) ANGEL PORGADOR, MARCO PIEROTTI, ROBERT DANN, Gerald Batist
13:55:00 SESSION 7 | STRATEGIES TO IMPROVE EFFICIENCY OF CLINICAL TRIALS Donald Berry
14:00:00 Challenges in early drug development JEAN CHARLES SORIA
14:25:00 Gateways to increased efficacy of drug development | From phase II to successful phase III and registration
14:50:00 Predicting clinical efficacy | Molecular and radiographic markers as heralds of drug response. Richard M Goldberg
15:15:00 FORUM OF OPEN DISCUSSION WITH ATTENDEES | From random to patient selected clinical trials: How should competing trials be prioritized? Defining thresholds for improved efficiency in clinical trials?
16:00:00 Coffee Break, network discussions and poster review
16:25:00 SESSION 8 | BREAKTHROUGH CONCEPTS AND TECHNOLOGIES DEVELOPMENTS Vladimir Lazar
16:30:00 Integration of multi-omics & biomarker strategies
16:55:00 Medical next generation sequencing: Translational medicine aiming to improve health care efficiency
17:20:00 Universal biomarker technology for cancer diagnostics: a joint development of Institut Gustave Roussy-Life Technologies
17:45:00 Personalized proteomics for cancer - unrealistic promises or true potential?
18:10:00 Refreshment break
18:25:00 CONCLUSION | THE URGENT NEED FOR INCREASED ACCESS OF PATIENTS FROM DIVERSE POPULATIONS TO INNOVATIVE CLINICAL TRIALS JOHN MENDELSOHN, Alexander Eggermont
18:30:00 Personalized medicine, synthesis of the 3rd WIN annual symposium and perspectives Richard L Schilsky
19:00:00 A perspective from patient advocacy: The urgent need to translate scientific progress to improve the life of cancer patients
20:30:00 GALA DINNER
Friday, July 8, 2011
08:30:00 General Assembly of the WIN Consortium (business meeting, restricted to members and open to non members by request and invitation only) JOHN MENDELSOHN
08:35:00 6 meeting rooms will be at your disposal for intervals of 45 minutes. Reservations may be made online at www.mfcongres.comfrom June 15th.
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.